These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27091119)

  • 21. Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study.
    Iwańczak BM; Kierkuś J; Ryżko J; Szczepanik M; Więcek S; Czaja-Bulsa G; Kacperska M; Korczowski B; Maślana J; Iwańczak F
    Adv Clin Exp Med; 2017; 26(1):57-61. PubMed ID: 28397433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients.
    Duijvis NW; Ten Hove AS; Ponsioen CI; van den Brink GR; Buskens CJ; Bemelman WA; Te Velde AA; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2016 Jul; 10(7):821-7. PubMed ID: 26818660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.
    Kevans D; Murthy S; Mould DR; Silverberg MS
    J Crohns Colitis; 2018 May; 12(6):662-669. PubMed ID: 29659758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
    Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
    J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of prednisolone tapering on effectiveness of infliximab in patients with ulcerative colitis: data from a retrospective cohort.
    Ovesen PD; Attauabi M; Ilvemark JFKF; Wewer MD; Warren DJ; Burisch J; Klaasen RA; Bolstad N; Steenholdt C; Seidelin JB
    BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38719549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis.
    Dean KE; Hikaka J; Huakau JT; Walmsley RS
    J Gastroenterol Hepatol; 2012 Mar; 27(3):487-92. PubMed ID: 22098019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.
    Williams JG; Alam MF; Alrubaiy L; Arnott I; Clement C; Cohen D; Gordon JN; Hawthorne AB; Hilton M; Hutchings HA; Jawhari AU; Longo M; Mansfield J; Morgan JM; Rapport F; Seagrove AC; Sebastian S; Shaw I; Travis SP; Watkins A
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):15-24. PubMed ID: 27595142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
    Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
    Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
    Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
    Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
    Seow CH; Newman A; Irwin SP; Steinhart AH; Silverberg MS; Greenberg GR
    Gut; 2010 Jan; 59(1):49-54. PubMed ID: 19651627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis.
    de Bruyn M; Arijs I; Wollants WJ; Machiels K; Van Steen K; Van Assche G; Ferrante M; Rutgeerts P; Vermeire S; Opdenakker G
    Inflamm Bowel Dis; 2014 Jul; 20(7):1198-207. PubMed ID: 24871805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.
    Kim EH; Kim DH; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
    Gut Liver; 2015 Sep; 9(5):601-6. PubMed ID: 25473080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L; Kolho KL
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis.
    Kim ES; Kim SK; Park DI; Kim HJ; Lee YJ; Koo JS; Kim ES; Yoon H; Lee JH; Kim JW; Shin SJ; Kim HW; Kim HS; Park YS; Kim YS; Kim TO; Lee J; Choi CH; Han DS; Chun J; Kim HS;
    J Clin Gastroenterol; 2023 Jul; 57(6):601-609. PubMed ID: 35470308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis.
    Bressler B; Law JK; Al Nahdi Sheraisher N; Atkinson K; Byrne MF; Chung HV; Fishman M; Partovi N; Pearson D; Penner R; Enns RA
    Can J Gastroenterol; 2008 Nov; 22(11):937-40. PubMed ID: 19018340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis.
    Farkas K; Molnár T; Szepes Z
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):695-702. PubMed ID: 24738535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab.
    Magro F; Lopes SI; Lopes J; Portela F; Cotter J; Lopes S; Moreira MJ; Lago P; Peixe P; Albuquerque A; Rodrigues S; Silva MR; Monteiro P; Lopes C; Monteiro L; Macedo G; Veloso L; Camila C; Afonso J; Geboes K; Carneiro F;
    J Crohns Colitis; 2016 Dec; 10(12):1407-1416. PubMed ID: 27226417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.